These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

115 related articles for article (PubMed ID: 12953338)

  • 1. Using multiple drug exposure levels to optimize power in pharmacogenetic trials.
    Judson R
    J Clin Pharmacol; 2003 Aug; 43(8):816-24. PubMed ID: 12953338
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Trick or treat: the effect of placebo on the power of pharmacogenetic association studies.
    Singer C; Grossman I; Avidan N; Beckmann JS; Pe'er I
    Hum Genomics; 2005 Mar; 2(1):28-38. PubMed ID: 15814066
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacogenetics in drug regulation: promise, potential and pitfalls.
    Shah RR
    Philos Trans R Soc Lond B Biol Sci; 2005 Aug; 360(1460):1617-38. PubMed ID: 16096112
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Genetic techniques for pharmacogenetic analyses.
    van der Straaten T; van Schaik RH
    Curr Pharm Des; 2010; 16(2):231-7. PubMed ID: 20214624
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [State of the art of pharmacogenetic diagnostics in drug therapy].
    Kirchheiner J; Seeringer A; Brockmöller J
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2006 Oct; 49(10):995-1003. PubMed ID: 17013776
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Pharmacogenetics: from discovery to patient care.
    Shin J; Kayser SR; Langaee TY
    Am J Health Syst Pharm; 2009 Apr; 66(7):625-37. PubMed ID: 19299369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacogenetic aspects of drug-induced torsade de pointes: potential tool for improving clinical drug development and prescribing.
    Shah RR
    Drug Saf; 2004; 27(3):145-72. PubMed ID: 14756578
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The medical and economic roles of pipeline pharmacogenetics: Alzheimer's disease as a model of efficacy and HLA-B(*)5701 as a model of safety.
    Roses AD
    Neuropsychopharmacology; 2009 Jan; 34(1):6-17. PubMed ID: 18923406
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Comparison of Nonlinear Mixed Effects Models and Noncompartmental Approaches in Detecting Pharmacogenetic Covariates.
    Tessier A; Bertrand J; Chenel M; Comets E
    AAPS J; 2015 May; 17(3):597-608. PubMed ID: 25693489
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacogenetic application in drug development and clinical trials.
    Shi MM; Bleavins MR; de la Iglesia FA
    Drug Metab Dispos; 2001 Apr; 29(4 Pt 2):591-5. PubMed ID: 11259358
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Potential of adaptive clinical trial designs in pharmacogenetic research.
    van der Baan FH; Knol MJ; Klungel OH; Egberts AC; Grobbee DE; Roes KC
    Pharmacogenomics; 2012 Apr; 13(5):571-8. PubMed ID: 22462749
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Integrating rare genetic variants into pharmacogenetic drug response predictions.
    Ingelman-Sundberg M; Mkrtchian S; Zhou Y; Lauschke VM
    Hum Genomics; 2018 May; 12(1):26. PubMed ID: 29793534
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Development of analytical technology in pharmacogenetic research.
    Daly AK
    Naunyn Schmiedebergs Arch Pharmacol; 2004 Jan; 369(1):133-40. PubMed ID: 14513205
    [TBL] [Abstract][Full Text] [Related]  

  • 14. SurvivalGWAS_Power: a user friendly tool for power calculations in pharmacogenetic studies with "time to event" outcomes.
    Syed H; Jorgensen AL; Morris AP
    BMC Bioinformatics; 2016 Dec; 17(1):523. PubMed ID: 27931206
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Clinical pharmacogenetics: how do we ensure a favorable future for patients?
    Wiltshire T; Dong OM
    Pharmacogenomics; 2018 Apr; 19(6):553-562. PubMed ID: 29620450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Enabling large-scale pharmacogenetic studies by high-throughput mutation detection and genotyping technologies.
    Shi MM
    Clin Chem; 2001 Feb; 47(2):164-72. PubMed ID: 11159763
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Implementation of inpatient models of pharmacogenetics programs.
    Cavallari LH; Lee CR; Duarte JD; Nutescu EA; Weitzel KW; Stouffer GA; Johnson JA
    Am J Health Syst Pharm; 2016 Dec; 73(23):1944-1954. PubMed ID: 27864202
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacogenomics of warfarin: uncovering a piece of the warfarin mystery.
    Gulseth MP; Grice GR; Dager WE
    Am J Health Syst Pharm; 2009 Jan; 66(2):123-33. PubMed ID: 19139476
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pharmacogenetics in biological perspective.
    Kalow W
    Pharmacol Rev; 1997 Dec; 49(4):369-79. PubMed ID: 9443163
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [How to individualize drug therapy based on pharmacogenetic information? A systematic review of published guidelines].
    Hafner S; Haubensak S; Paul T; Zolk O
    Dtsch Med Wochenschr; 2016 Oct; 141(21):e183-e202. PubMed ID: 27750332
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 6.